Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H18O12P2.4Na |
| Molecular Weight | 580.2349 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[Na+].[Na+].COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C(OP([O-])([O-])=O)=C1OP([O-])([O-])=O
InChI
InChIKey=NRKFVEPAQNCYNJ-YGGCHVFLSA-J
InChI=1S/C18H22O12P2.4Na/c1-25-13-8-7-12(16(29-31(19,20)21)18(13)30-32(22,23)24)6-5-11-9-14(26-2)17(28-4)15(10-11)27-3;;;;/h5-10H,1-4H3,(H2,19,20,21)(H2,22,23,24);;;;/q;4*+1/p-4/b6-5-;;;;
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H18O12P2 |
| Molecular Weight | 488.2758 |
| Charge | -4 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Oxi0-4503 (now known as combretastatin A1 phosphate), a diphosphate prodrug of combretastatin A1, was developed by Mateon therapeutics as a second-generation, dual-mechanism vascular disrupting agent from the combretastatin family. On November 21, 2012, Oxi-4503 has been granted orphan designation by the US Food and Drug Administration for the treatment of acute myelogenous leukemia. It is known that the orphan drug designation qualifies a company for several benefits, including the potential for market exclusivity, development grants, and tax credits. Oxi0-4503 is currently participating in phase I/II clinical trial the treatment of patients with acute myelogenous leukemia or myelodysplastic syndrome. In addition, phase I clinical trial was successfully completed where was studied the safety of Oxi0-4503 in patients with advanced solid tumors.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Alterations in vascular architecture and permeability following OXi4503 treatment. | 2008-01 |
|
| The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. | 2007-11 |
|
| Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis. | 2007-08-19 |
|
| Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. | 2006-07-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:23:13 GMT 2025
by
admin
on
Mon Mar 31 23:23:13 GMT 2025
|
| Record UNII |
3D67LX3H83
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
288847-34-7
Created by
admin on Mon Mar 31 23:23:13 GMT 2025 , Edited by admin on Mon Mar 31 23:23:13 GMT 2025
|
PRIMARY | |||
|
3D67LX3H83
Created by
admin on Mon Mar 31 23:23:13 GMT 2025 , Edited by admin on Mon Mar 31 23:23:13 GMT 2025
|
PRIMARY | |||
|
6918545
Created by
admin on Mon Mar 31 23:23:13 GMT 2025 , Edited by admin on Mon Mar 31 23:23:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|